Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

HHS Logo Eagle IconU.S. Department of Health and Human Services

Office of Science and Data Policy (SDP)

The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.

The Office of Science and Data Policy includes several components:

Topic Areas:

  • HHS Data Council
  • Regulatory Impact Analysis
  • Strategic Planning
  • Information Quality Guidelines
  • Prevention and wellness
  • Public health systems and functions
  • Food safety and nutrition
  • Drugs and devices
  • Tobacco control and prevention
  • Biomedical research and development
  • Economic analysis
  • Emergency preparedness, response, and recovery
  • Data and statistical policy
  • Health disparities and vulnerable populations
  • Health information technology
  • Microsimulation
  • Privacy policy

Reports

Displaying 21 - 30 of 183. 10 per page. Page 3.

Advanced Search
ASPE Issue Brief

Impacts of a Nonprofit Membership-Based Pharmaceutical Company on Volume of Drugs Sold and Drug Prices: A Case Study

We report findings of a case study of Civica Rx, a U.S. nonprofit pharmaceutical company whose model is based on long-term hospital membership agreements with minimum volume commitments and buffer stock requirements.Related Products:
Report

The Potential Role of The Nonprofit Pharmaceutical Industry in Addressing Shortages and Increasing Access to Essential Medicines and Low-Cost Medicines

We report findings of a study that described the emerging nonprofit pharmaceutical industry and its commercialization activities to enhance access to affordable and essential drugs, or resiliency in the supply chains of medical products.
Research Summary

Costs of Drug Development and Research and Development Intensity in the US, 2000-2018

This landing page represents the abstract of a paper published in JAMA. The full text of the article is available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820562.Abstract
Report

FY 2024 HHS Capacity Assessment Check In

The FY2024 Capacity Assessment Check In is part of the Department of Health and Human Services’ (HHS) multi-year approach for addressing the primary capacity building needs identified through the initial FY2023-2026 HHS Capacity Assessment.
ASPE Issue Brief

HHS Actions to Enhance Diversity in Clinical Research

Clinical research forms the foundation for understanding and developing treatments for all types of medical conditions, but participants often do not reflect the diversity of the nation – in terms of sex, age, race, ethnicity, disability status, gender identity, socioeconomic status, geography, or other characteristics.
Report

Impact of Drug Shortages on Patients in the United States: A Case Study of Three Drugs

Drug shortages are a persistent problem that can cause substantial disruption in patient treatment regimens and adversely impact a patient’s health. Drug shortages can have severe consequences for patients, including high costs, delayed care, and potential medication errors or unintended side effects when using alternative or unfamiliar drugs.
Report

The Availability, Quality, and Use of Administrative Data to Identify and Reduce Health and Human Services-Related Disparities: A Survey of HHS-Funded Programs and Interventions

Executive Orders No. 13985 (2021) and 14091 (2023) require federal agencies to ensure that their policies and services, including data collection, advance equitable outcomes for all populations. The Assistant Secretary for Planning and Evaluation (ASPE) and the U.S.
White Paper

Policy Considerations to Prevent Drug Shortages and Mitigate Supply Chain Vulnerabilities in the United States

Report

2025 HHS Evaluation Plan

The FY 2025 HHS Evaluation Plan details the Department of Health and Human Services’ (HHS) efforts to answer the priority questions presented in the current HHS Evidence Building Plan. This plan provides both an overview of HHS evaluation activities planned for FY 2025 and detailed information for each new and continuing evaluation effort.
Research Summary

Premarket Notifications and Patents for Breast Pumps Before and After the ACA

This study investigated whether ACA policies to increase access to breast pumps and lactation care were associated with innovation in the market for breast pumps.